Axsome Therapeutics, Inc. (0HKF.L)
USD 94.11
(0.14%)
USD 94.11
(0.14%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 588.23 Million USD | 77.46% |
| 2022 | 331.47 Million USD | 197.97% |
| 2021 | -338.35 Million USD | -281.78% |
| 2020 | 186.13 Million USD | -15.6% |
| 2019 | 220.54 Million USD | 1334.07% |
| 2018 | 15.37 Million USD | -56.75% |
| 2017 | 35.55 Million USD | -6.95% |
| 2016 | 38.21 Million USD | -22.14% |
| 2015 | 49.07 Million USD | 1661.29% |
| 2014 | 2.78 Million USD | 32.85% |
| 2013 | 2.09 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 548.22 Million USD | 0.46% |
| 2024 Q1 | 545.72 Million USD | -7.23% |
| 2023 Q2 | 611.63 Million USD | 57.16% |
| 2023 Q1 | 389.17 Million USD | 17.41% |
| 2023 FY | 588.23 Million USD | 77.46% |
| 2023 Q4 | 588.23 Million USD | -2.1% |
| 2023 Q3 | 600.85 Million USD | -1.76% |
| 2022 Q2 | 180.55 Million USD | 103.88% |
| 2022 Q4 | 331.47 Million USD | -2.21% |
| 2022 Q1 | 88.56 Million USD | 126.17% |
| 2022 FY | 331.47 Million USD | 197.97% |
| 2022 Q3 | 338.95 Million USD | 87.73% |
| 2021 Q2 | 143.26 Million USD | -14.16% |
| 2021 Q4 | -338.35 Million USD | -390.19% |
| 2021 FY | -338.35 Million USD | -281.78% |
| 2021 Q3 | 116.59 Million USD | -18.61% |
| 2021 Q1 | 166.9 Million USD | -10.33% |
| 2020 FY | 186.13 Million USD | -15.6% |
| 2020 Q1 | 197.8 Million USD | -10.31% |
| 2020 Q2 | 190.98 Million USD | -3.44% |
| 2020 Q3 | 203.62 Million USD | 6.62% |
| 2020 Q4 | 186.13 Million USD | -8.59% |
| 2019 Q3 | 44.43 Million USD | -18.87% |
| 2019 Q1 | 43.9 Million USD | 185.46% |
| 2019 FY | 220.54 Million USD | 1334.07% |
| 2019 Q2 | 54.77 Million USD | 24.78% |
| 2019 Q4 | 220.54 Million USD | 396.29% |
| 2018 Q3 | 16.12 Million USD | -25.77% |
| 2018 Q1 | 27.93 Million USD | -21.42% |
| 2018 FY | 15.37 Million USD | -56.75% |
| 2018 Q4 | 15.37 Million USD | -4.63% |
| 2018 Q2 | 21.72 Million USD | -22.24% |
| 2017 Q1 | 46.41 Million USD | 21.46% |
| 2017 FY | 35.55 Million USD | -6.95% |
| 2017 Q4 | 35.55 Million USD | 9.01% |
| 2017 Q3 | 32.61 Million USD | -16.46% |
| 2017 Q2 | 39.04 Million USD | -15.88% |
| 2016 Q1 | 45.14 Million USD | -8.0% |
| 2016 FY | 38.21 Million USD | -22.14% |
| 2016 Q4 | 38.21 Million USD | 9.43% |
| 2016 Q3 | 34.91 Million USD | -12.72% |
| 2016 Q2 | 40 Million USD | -11.39% |
| 2015 FY | 49.07 Million USD | 1661.29% |
| 2015 Q2 | 6.87 Million USD | 0.0% |
| 2015 Q4 | 49.07 Million USD | 699.6% |
| 2015 Q3 | 6.13 Million USD | -10.73% |
| 2015 Q1 | - USD | -100.0% |
| 2014 FY | 2.78 Million USD | 32.85% |
| 2014 Q4 | 2.78 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | 2.09 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -17.847% |
| Dynavax Technologies Corporation | 997.09 Million USD | 41.005% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 58.251% |
| Perrigo Company plc | 10.8 Billion USD | 94.558% |
| Illumina, Inc. | 10.11 Billion USD | 94.182% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.404% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 24.619% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.274% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 97.795% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -164.369% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.222% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -795.473% |
| Waters Corporation | 4.62 Billion USD | 87.286% |
| Biogen Inc. | 26.84 Billion USD | 97.809% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -255.817% |
| Evolus, Inc. | 188.99 Million USD | -211.239% |
| Adicet Bio, Inc. | 207.29 Million USD | -183.768% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -367.433% |
| bluebird bio, Inc. | 619.16 Million USD | 4.995% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -185.835% |
| FibroGen, Inc. | 423.52 Million USD | -38.889% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 94.535% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1980.602% |
| Homology Medicines, Inc. | 47.05 Million USD | -1150.05% |
| Geron Corporation | 394.07 Million USD | -49.27% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 84.641% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 24.38% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 50.927% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -59.634% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 54.785% |
| Zoetis Inc. | 14.28 Billion USD | 95.882% |
| Abeona Therapeutics Inc. | 64 Million USD | -819.09% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 82.47% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 91.402% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.412% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -951.379% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 80.327% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -255.421% |
| Verastem, Inc. | 149.71 Million USD | -292.896% |
| Nektar Therapeutics | 398.03 Million USD | -47.786% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -197.984% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 81.981% |
| OPKO Health, Inc. | 2.01 Billion USD | 70.759% |
| Exelixis, Inc. | 2.94 Billion USD | 80.008% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 81.908% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 5.355% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -281.016% |
| uniQure N.V. | 831.68 Million USD | 29.272% |
| Imunon, Inc. | 21.91 Million USD | -2583.795% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 43.937% |
| Insmed Incorporated | 1.32 Billion USD | 55.766% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 66.062% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 37.229% |
| TG Therapeutics, Inc. | 329.58 Million USD | -78.477% |
| Incyte Corporation | 6.78 Billion USD | 91.327% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 67.942% |